
Pheast Therapeutics: Innovating cancer immunotherapy with novel checkpoint therapies.
Pheast Therapeutics, founded with a mission to innovate cancer immunotherapy, focuses on developing novel checkpoint therapies that harness the innate immune system to combat cancer. The company is dedicated to creating treatments that target specific immune checkpoints, such as their lead candidate PHST001, an anti-CD24 macrophage checkpoint inhibitor. Pheast aims to revolutionize the cancer treatment landscape by enhancing the body's natural ability to fight tumors, targeting a market that includes patients with various forms of cancer.
Notable achievements for Pheast Therapeutics include raising $76 million in Series A funding and being featured as one of Nature Biotechnology’s top academic spinouts. The company has also unveiled promising preclinical data for PHST001, highlighting its potential in cancer immunotherapy. With significant backing from investors and recognition from industry leaders, Pheast Therapeutics is poised to make a substantial impact on the future of cancer treatment by advancing innovative therapies that leverage the immune system's power.

Checkpoint Therapeutics
checkpointtx.com

NextPoint Therapeutics
nextpointtx.com

Parthenon Therapeutics
parthenontx.com

Phanes Therapeutics
phanesthera.com

DEM Biopharma
dembiopharma.com

Ostentus Therapeutics

PineTree Therapeutics
pinetreetx.com

Faeth Therapeutics

Onchilles Pharma

Umoja Biopharma

Thunder Biotech
thunderbiotech.com

PanTher Therapeutics
panthertx.com

Palm Therapeutics

PNP Therapeutics

Partner Therapeutics
partnertx.com
Companies similar to Pheast Therapeutics include Checkpoint Therapeutics, NextPoint Therapeutics, Parthenon Therapeutics and Phanes Therapeutics.
Pheast Therapeutics was founded in 2020.
Pheast Therapeutics' headquarters is located in Palo Alto, CA, US.
Pheast Therapeutics' most recent funding round was for $76M (USD) in April 2022.
As of Apr 26, 2022, Pheast Therapeutics has raised a total of $76M (USD).
Pheast Therapeutics has 23 employees as of Feb 5, 2024.